Inflazyme Pharmaceuticals Ltd. will undergo a corporate restructuring following its recent announcement on the Phase IIb CAPSICS study results. The results demonstrated a surprisingly large placebo response in the asthma trial, which obscured any potential effects of the drug. The restructuring, which takes effect immediately, will reduce the company’s expenditures in an effort to improve its cash position. The restructuring involves a reduction of approximately 70% of the company&#82...